Founded by former scientists and entrepreneurs from Organovo and Ardea Biosciences, Viscient Biosciences is developing a drug discovery platform that combines 3D tissue technology with genomics, transcriptomics, and metabolomics analysis. Their focus is on addressing significant unmet medical needs, starting with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). By leveraging advanced three-dimensional biology technologies, Viscient aims to gain a better understanding of diseases and create impactful treatments for patients.